RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

By designing quality into trials, we focus on the most critical data and create a framework for efficiently identifying and addressing any risks to patients, the integrity of data, or regulatory compliance. While part of regulatory guidance, consistent interpretation of RBQM approaches by regulatory inspectors is an area of concern. In such a highly regulated industry that is notably slow to adopt change, biopharmaceutical companies and CROs are still debating how to go with evidence-backed documentation to satisfy regulatory requirements when using risk-based approaches.

In the third episode of our RBQM podcast series, Amy Kissam-Sands, Senior Vice President of Clinical Operations and Dr. Kristin Murphy, Senior Director and Global Head of the Change and Adoption Center of Excellence, discuss how to work within the regulatory guardrails when establishing a risk assessment framework.

 

Return to Insights Center

Related Insights

Blog

Leveraging the draft FDA Guidance on PBPK for your drug development program

Feb 24, 2021

Blog

AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression

Mar 19, 2024

Blog

Summary and assessment: Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products: Discussion Paper and Request for Feedback (FDA)

Mar 7, 2024

Blog

Summary and assessment of EMA’s reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle

Mar 7, 2024

Blog

Regulatory acceptability of AI: Current perspectives

Mar 7, 2024

Playbook

Are you using real-world evidence?

Feb 1, 2023

Blog

FDA’s new priority voucher review program: Potential implications and next steps for sponsors

Jun 20, 2025

Whitepaper

The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

Mar 9, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Whitepaper

Optimizing Biosensor-based Trials

Feb 1, 2023

Webinar

How to navigate China’s regulatory environment

Feb 15, 2023

Related Insights

Blog

Leveraging the draft FDA Guidance on PBPK for your drug development program

Feb 24, 2021

Blog

AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression

Mar 19, 2024

Blog

Summary and assessment: Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products: Discussion Paper and Request for Feedback (FDA)

Mar 7, 2024

Blog

Summary and assessment of EMA’s reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle

Mar 7, 2024

Blog

Regulatory acceptability of AI: Current perspectives

Mar 7, 2024

Playbook

Are you using real-world evidence?

Feb 1, 2023

Show more